Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alirocumab (Primary) ; Atorvastatin; Rosuvastatin
  • Indications Acute coronary syndromes; Cardiovascular disorders; Dyslipidaemias; Myocardial infarction; Stroke; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms ODYSSEY-Outcomes
  • Sponsors Sanofi

    • Most Recent Events

    • 13 Nov 2023 Results assessing comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events, presented at the American Heart Association Scientific Sessions 2023.
    • 13 Nov 2023 Results (n=9149) assessing Cardiovascular Events After ACS on High-Intensity Statin Therapy presented at the American Heart Association Scientific Sessions 2023
    • 01 Oct 2023 Results assessing the risk of revascularization after acute coronary syndrome was modified by the level of lipoprotein and treatment with alirocumab or placebo, published in the Canadian Journal of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top